ログインで組織・契約価格をご覧ください。
サイズを選択してください
表示を変更する
| サイズ/SKU | 在庫状況 | 単価 |
|---|---|---|
25 mg | 出荷予測2026年11月10日from市川市大町368 | ￥165,000 |
この商品について
実験式（ヒル表記法）:
C13H14BrNO2
CAS番号:
分子量:
296.16
NACRES:
NA.24
MDL number:
UNSPSC Code:
41116107
eCl@ss:
25140904
grade
pharmaceutical analytical impurity (PAI)
agency
USP
API family
aripiprazole
manufacturer/tradename
USP
application(s)
pharmaceutical
format
neat
storage temp.
2-8°C
SMILES string
BrCCCCOc1cc2nc(ccc2cc1)O
InChI key
MBOHAVAGDOGRBS-UHFFFAOYSA-N
General description
Find answers to frequently asked questions on USP products in USP FAQs.
Aripiprazole Bromobutoxyquinolinone Analog is a USP Pharmaceutical Analytical Impurity (PAI).
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Aripiprazole.
For more information about this PAI, visit here.
USP PAI are a product line of impurities suitable for research and analytical purposes, which help to ensure the quality and safety of medicines.
Associated Drug Substance: Aripiprazole.
For more information about this PAI, visit here.
Application
Aripiprazole Bromobutoxyquinolinone Analog (USP PAI) is intended for use in analytical testing to detect, identify, and measure pharmaceutical impurities.
Features and Benefits
USP PAI advance your early analytical R&D and process development. PAI can be used in the following applications:
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
1. Conduct analytical tests during early formulation feasibility studies.
2. Determine degradation impurities produced during stress studies.
3. Develop, validate, and transfer analytical methods.
4. Perform spiking studies during process R&D to demonstrate depletion upon recrystallization.
5. Record retention times and/or spectra
6. Determine relative response factors.
7. Identify unknown impurities that formed during ICH stability conditions.
8. Identify impurities that are present in the Reference Listed Drug
9. Test for and profile impurities not listed in drug substance and drug product monographs.
Analysis Note
These products are for test and assay use only. They are not meant for administration to humans or animals and cannot be used to diagnose, treat, or cure diseases of any kind.
Other Notes
Sales restrictions may apply.
保管分類
11 - Combustible Solids
WGK
WGK 3
引火点 (F)
Not applicable
引火点（°C）
Not applicable